[2015. 05. 22] SIC Seminar: 5/22(Fri) 13:30, Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic m
Dear SIC students,
It is my pleasure to announce the SIC Colloquium by Dr.Hyojung Paik, who is currently with the University of California, San Francisco.
For detailed information, please see the following:
Host: Prof. Hojung Nam / Language: Korean
Friday, May 22, 2015, 13:30-15:00, #203, SIC-B Bldg. 2nd Floor
Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records
By Hyojung Paik, PhD
Post-Doc., University of California, San Francisco
Prediction of new disease indications for approved drugs by computational methods has been based largely on the genomics signatures of drugs and diseases. We propose a method for drug repositioning that uses the clinical signatures extracted from over 13 years of electronic medical records from a tertiary hospital, including .9.4 M laboratory tests from .530,000 patients, in addition to diverse genomics signatures. Cross-validation using over 17,000 known drug–disease associations shows this approach outperforms various predictive models based on genomics signatures and a well-known ‘‘guilt-by-association’’ method. Interestingly, the prediction suggests that terbutaline sulfate, which is widely used for asthma, is a promising candidate for amyotrophic lateral sclerosis for which there are few therapeutic options. In vivo tests using zebrafish models found that terbutaline sulfate prevents defects in axons and neuromuscular junction degeneration in a dose-dependent manner. A therapeutic potential of terbutaline sulfate was also observed when axonal and neuromuscular junction degeneration have already occurred in zebrafish model. Cotreatment with a b2-adrenergic receptor antagonist, butoxamine, suggests that the effect of terbutaline is mediated by activation of b2-adrenergic receptors.